Please assess the completion status of the following clinical trial:

Trial Title: Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man and women, aged from 18 to 80 years.~* Social security affiliation~* Inclusion from day 3 to day 15 after stroke or brain haemorrhage~* Hemiparesia with upper limb motor deficit (Fugl-Meyer score - hand \< or = 10)~* Informed consent~Exclusion Criteria:~* Score NIHSS \> 20~* Depression (criteria DSM5-R) with MADRS score \> 19~* History of recurrent bipolar or depressive disorders.~* History of behavior or suicidal idea~* Family history of extension of the interval QT or congenital long interval QT~* History of clinical stroke~* Aphasia preventing correct evaluation of motor and depression scales.~* Patients treated by antidepressant drugs, monoamine oxidase inhibitor (IMAO), and neuroleptics in the past month~* Benzodiazepines within 48 hours preceding inclusion.~* Intolerance or allergy to fluoxetine (Sandoz® 20 mg pill)~* Severe swallowing disorders preventing oral administration of the treatment~* Planned carotid surgery~* Pregnant or breast-feeding woman~* Hepatic failure (TGO and TGP \>2N); severe renal failure (creatinine \>180micromol/l)~* Concomitant severe disease not allowing follow-up.~* Participation to another therapeutic study.~* Contraindication to MRI and TMS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).